Dr. Leahu Dental Clinics has raised capital through a bond private placement to accelerate its expansion plans
Dr. Leahu Dental Clinics has raised US$2.4 million through a bond private placement targeting local high-net-worth individuals and small asset managers. The bond issuance was listed on Bucharest Stock Exchange, is denominated in RON, has a three year maturity period (due in 2022) and a fixed annual coupon of 7.5%.
Dr. Leahu Dental Clinics is the leading chain of dental clinics in Romania, with ten locations across the country. Owned by its founder, the company offers a full spectrum of stomatology services, and plans to consolidate the local market both organically and through M&A.
Oaklins’ team in Romania, acted as private debt advisor and authorized consultant for the bond issuance, assisting Dr Leahu Dental Clinics’ shareholders all the way, from the start to the successful completion and listing of the financial instrument on the Bucharest Stock Exchange. During this process, the team initiated and advised on many aspects, including, among others, securing pre-commitments from cornerstone investors, deal structuring, and the bond pricing and sizing.
Talk to the deal team
Related deals
Dimainvest S.r.l. has launched a voluntary public tender offer for Shedir Pharma Group S.p.A.
Dimainvest S.r.l. has initiated a voluntary public tender offer for the shares of Shedir Pharma Group S.p.A.
Learn moreAfric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Learn moreXiel Limited has been acquired by MIS Healthcare
MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.
Learn more